Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Silver Nanoparticle Drug Combo Could Treat Brain-Eating Amoeba

By Kenny Walter | October 24, 2018

Silver nanoparticles may help a trio of drugs stop brain-eating amoeba.

Researchers from the American Chemical Society have coated silver nanoparticles with anti-seizure drugs to eliminate Naegleria fowleri—also known as brain-eating amoeba— , while saving the nearby human cells.

The researchers focused on three anti-seizure drugs—diazepam, phenobarbitone and phenytoin—to kill the amoeba., either alone or in combination with silver nanoparticles. The U.S. Food and Drug Administration has already approved all three of the drugs, which are known to cross the blood-brain barrier.

According to the researchers, the drugs could be more effective if they were attached to silver nanoparticles, which can improve delivery.. The silver nanoparticles also have their own antimicrobial effects that could be beneficial.

To test this, they chemically attached each of the three drugs to silver nanoparticles and examined their ability to kill amoebae.

Each of the three drugs alone could kill N. fowleri and Acanthameoba castellanii, another species of brain-eating amoeba., which causes blindness by entering the eyes through dirty contact lenses. However, all three drugs worked better when paired with the silver nanoparticles, protecting human cells from the microbes, while increasing the survival rate compared to the untreated infected human cells.

The researchers believe that the repurposed drugs bound to silver nanoparticles might kill the amoeba. by binding to protein receptors or ion channels on the single-celled organism’s membrane.

“Drugs alone and drugs conjugated silver nanoparticles were tested for amoebicidal, cysticidal and host-cells cytotoxicity assays,” the authors write. “In vitro amoebicidal assay showed potent amoebicidal effects for Diazepam, Phenobarbitone, and Phenytoin-conjugated AgNPs as compared to drugs alone against A. castellanii and N. fowleri. Nanoparticles were synthesized by sodium borohydride reduction of silver nitrate with drugs as capping agents.”

While central nervous system (CNS) infections with brain-eating amoebae remain rare, when they do strike they are almost universally fatal. Most of the causes of this condition result from inhaling warm, dirty water from ponds, hot springs or unchlorinated swimming pools.

Treatment for these conditions include antimicrobial drugs. However, these drugs can often cause severe side effects due to the high doses needed for them to enter the brain.

“A major challenge in the treatment against the infections caused by these amoebae is the discovery of novel compounds that can effectively cross the blood-brain barrier to penetrate CNS,” the authors write. “It is logical to test clinically-approved drugs against CNS diseases for their potential antiamoebic effects since they are known for effective blood-brain barrier penetration and effect eukaryotic cell targets.”

The study was published in ACS Chemical Neuroscience.  

Related Articles Read More >

For the first time, scientists grow beating human-pig hearts for 21 days
Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE